SQURPHARMA Stock Overview
Manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Square Pharmaceuticals PLC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳216.00 |
| 52 Week High | ৳249.80 |
| 52 Week Low | ৳197.20 |
| Beta | 0.24 |
| 1 Month Change | -0.46% |
| 3 Month Change | -2.66% |
| 1 Year Change | -0.46% |
| 3 Year Change | -6.25% |
| 5 Year Change | 13.91% |
| Change since IPO | 10,128.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| SQURPHARMA | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -0.3% | -0.2% | 1.0% |
| 1Y | -0.5% | -30.4% | -19.3% |
Return vs Industry: SQURPHARMA exceeded the BD Pharmaceuticals industry which returned -30.4% over the past year.
Return vs Market: SQURPHARMA exceeded the BD Market which returned -19.3% over the past year.
Price Volatility
| SQURPHARMA volatility | |
|---|---|
| SQURPHARMA Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BD Market | 7.0% |
| 10% least volatile stocks in BD Market | 2.6% |
Stable Share Price: SQURPHARMA has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: SQURPHARMA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 12,453 | Tapan Chowdhury | www.squarepharma.com.bd |
Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxidants, antiparasites, aromatase inhibitors, bone calcium regulators, erythropoiesis stimulating agents, gynae anti-infectives, magnesium, mineral supplements, non-narcotic analgesics, non-hormonals, non-steroidal anti-inflammatory drugs, antibacterials, vitamins, prolactin inhibitors, selective serotonin reuptake inhibitors, anti-rheumatic agents, steroids, antifungals, antivirals, antiprotozoals, topical ear and nasal preparations, and skin and urological preparations; and generic pharmaceuticals, infusions, lubricants, laxatives, and mouthwash. It also provides pharmaceuticals for cardiovascular, CNS, cough and cold, dialysis, digestive enzymes, eyes, hepatobiliary disorders, hyperphosphatemia, hypoactive sexual desire, inflammatory bowel, oncology, and respiratory tract infections.
Square Pharmaceuticals PLC. Fundamentals Summary
| SQURPHARMA fundamental statistics | |
|---|---|
| Market cap | ৳191.47b |
| Earnings (TTM) | ৳22.38b |
| Revenue (TTM) | ৳72.27b |
8.6x
P/E Ratio2.6x
P/S RatioIs SQURPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SQURPHARMA income statement (TTM) | |
|---|---|
| Revenue | ৳72.27b |
| Cost of Revenue | ৳39.81b |
| Gross Profit | ৳32.46b |
| Other Expenses | ৳10.08b |
| Earnings | ৳22.38b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.24 |
| Gross Margin | 44.91% |
| Net Profit Margin | 30.96% |
| Debt/Equity Ratio | 0.9% |
How did SQURPHARMA perform over the long term?
See historical performance and comparisonDividends
5.1%
Current Dividend Yield44%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 19:31 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Square Pharmaceuticals PLC. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| S M Toufique Imran | BRAC EPL Stock Brokerage Ltd |
| Asif Khan | EDGE Research & Consulting |
| Tanay Roy | IDLC Securities Limited |